The short version of Drug affinity complex fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-18. Anything still debated is marked as such rather than presented as settled.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
=== IBP Golden Pillar of Law Award === Duterte was conferred the Golden Pillar of Law Award on September 15, 2025, from the Davao City chapter of the Integrated Bar of the Philippines (IBP). Human rights lawyers and activists urged the IBP to revoke the award viewing that his role in the war on drugs contradicts with the spirit of the recognition. The national office of the IBP maintained Duterte's presumed innocence as it "do not confer guilt or grace beyond the reach of law" but nevertheless pledge to review rules concerning the award. IBP Davao insist that Duterte satisfy the criteria for the award based on professional longevity and standing status and that the Golden Pillar award does not "serve as an endorsement of political acts or personal ideologies".
== Early life == Pickston was born in Oldham, Lancashire, and grew up in Shaw, Lancashire, where she was raised by her grandfather, William Fawcett. Her father, Paul Fawcett, worked for British Telecom during her early years. Pickston attended Rishworth School. Her mother, whose surname is Yachan, is Thai.
Threonine is one of two proteinogenic amino acids with two stereogenic centers, the other being isoleucine. Threonine can exist in four possible stereoisomers with the following configurations: (2S,3R), (2R,3S), (2S,3S) and (2R,3R). However, the name L-threonine is used for one single stereoisomer, (2S,3R)-2-amino-3-hydroxybutanoic acid. The stereoisomer (2S,3S), which is rarely present in nature, is called L-allothreonine.
His political activism prompted the US State Department to deny him a passport in 1952, when he was invited to speak at a scientific conference in London. In a speech before the US Senate on June 6 of the same year, Senator Wayne Morse publicly denounced the action of the State Department, and urged the Passport Division to reverse its decision. Pauling and his wife Ava were then issued a "limited passport" to attend the conference. His full passport was restored in 1954, shortly before the ceremony in Stockholm where he received his first Nobel Prize. Joining Einstein, Bertrand Russell and eight other leading scientists and intellectuals, he signed the Russell-Einstein Manifesto issued July 9, 1955. He also supported the Mainau Declaration of July 15, 1955, signed by 52 Nobel Prize laureates. In May 1957, working with Washington University in St. Louis professor Barry Commoner, Pauling began to circulate a petition among scientists to stop nuclear testing. On January 15, 1958, Pauling and his wife presented a petition to United Nations Secretary General Dag Hammarskjöld calling for an end to the testing of nuclear weapons. It was signed by 11,021 scientists representing fifty countries. In February 1958, Pauling participated in a publicly televised debate with the atomic physicist Edward Teller about the actual probability of fallout causing mutations. Later in 1958, Pauling published No more war!, in which he not only called for an end to the testing of nuclear weapons but also an end to war itself.
They also have great physical strength; a bear weighing 120 lb (54 kg) was observed flipping over flat rocks weighing 310 to 325 lb (141 to 147 kg) with a single foreleg. They move with a rhythmic, sure-footed gait and can run at speeds of up to 25–30 mph (40–48 km/h). American black bears have good eyesight and have been proven experimentally to be able to learn visual color discrimination tasks faster than chimpanzees and just as fast as domestic dogs. They are also capable of rapidly learning to distinguish different shapes, such as small triangles, circles and squares.
Sources: en.wikipedia.org
== Detergents, salts & enzymes == Cell lysis is a critical step in the purification of enzymes from bacterial cells, various components are commonly included in lysing buffers to facilitate effective cell disruption and release of the target enzyme. These components include detergents, salts, and enzymes, each playing a specific role in the lysis process. Examples of detergents used in lysing buffers include: Detergents: Detergents are amphipathic molecules that possess both hydrophilic and hydrophobic properties. In the context of cell lysis, detergents act by disrupting the lipid bilayer of the bacterial cell membrane, leading to membrane permeabilization and release of intracellular components, including the target enzyme. Commonly used detergents in lysing buffers include: a. Triton X-100: a nonionic detergent frequently employed due to its mild and effective membrane-disrupting properties, it solubilizes lipids and membrane proteins, allowing the release of intracellular contents. b. Sodium dodecyl sulfate (SDS): an anionic detergent that denatures proteins by disrupting their secondary and tertiary structures, it solubilizes cellular membranes and aids in protein extraction. c. Tween-20: a nonionic detergent is milder compared to SDS and Triton X-100. It assists in membrane permeabilization and solubilization of proteins without causing significant denaturation. Salts: Salts are crucial components of lysing buffers as they help maintain optimal cellular conditions and provide ionic strength to facilitate cell disruption.
The theory of thermoresponsive polymer (similarly, microgels) begins in the 1940s with work from Flory and Huggins who both independently produced similar theoretical expectations for polymer in solution with varying temperature. The effects of external stimuli on particular polymers were investigated in the 1960s by Heskins and Guillet. They established 32°C as the lower critical solution temperature (LCST) for poly(N-isopropylacrylamide). While PNIPA was synthesised soon after the synthesis of acrylamide monomer, its first patented use was as a rodent repellent.
Pseudouridine is an RNA modification that is introduced post-translationally, meaning after the RNA is transcribed. The proteins that facilitate this are called pseudouridine synthases (PUS) and are found in all kingdoms of life. Most research has been conducted on how PUS modify tRNA, so mechanisms involving snRNA and mRNA are not clearly defined. PUS can vary on RNA specificity, structure, and isomerization mechanisms. PUS enzymes are divided into five families which share an active sequence and important structural motifs.
== Pharmacokinetics and pharmacogenetics == It is bioactivated hepatically to its primary metabolite, N-desethylamodiaquine, by the cytochrome p450 enzyme CYP2C8. Among amodiaquine users, several rare but serious side effects have been reported and linked to variants in the CYP2C8 alleles. CYP2C8*1 is characterized as the wild-type allele, which shows an acceptable safety profile, while CYP2C8*2, *3 and *4 all show a range of "poor metabolizer" phenotypes. People who are poor metabolizers of amodiaquine display lower treatment efficacy against malaria, as well as increased toxicity. Several studies have been conducted to determine the prevalence of CYP2C8 alleles amongst malaria patients in East Africa, and have tentatively shown the variant alleles have significant prevalence in that population. About 3.6% of the population studied showed high risk for a poor reaction to or reduced treatment outcomes when treated with amodiaquine. This information is useful in developing programs of pharmacovigilance in East Africa, and have important clinical considerations for prescribing antimalarial medications in regions with high CYP2C8 variant frequency.
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.